Bradley Merrill Thompson, Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in Law360, in “FDA's Eased Oversight Is Good Omen for Health IT,” by Jeff Overley.
Following is an excerpt:
“Those are incredibly important extensions of FDA’s policy of enforcement discretion,” Epstein Becker Green member Bradley Merrill Thompson said. …
“I do believe these guidances bode well for future [health] IT-related guidances,” Thompson said. “But of course, we will have to wait to see.”
